Taro Pharma (TARO) Misses Q4 EPS by 68c

Taro Pharma (NYSE: TARO) reported Q4 EPS of $0.19, $0.68 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $139.2 million versus the consensus estimate of $163.12 million.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• First Industrial Realty (FR) Tops Q1 EPS by 21c
• William Penn Bancorporation (WMPN) Tops Q3 EPS by 1c
• Crown Castle (CCI) Tops Q1 EPS by 1c; maintains outlook for FY24